Fecal Fat - Long Chain Fatty Acids Test · Stool

Your stool carries a quiet record of what your digestive tract did with the fat in your last few meals. When digestion and absorption work well, almost all of the fat you eat disappears into your bloodstream before waste leaves your body. When something is broken anywhere along that chain, from pancreatic enzymes to bile flow to the lining of your small intestine, fat starts slipping through and shows up in your stool.

LCFAs (long chain fatty acids) are the most abundant type of fat in a typical diet, and measuring how much ends up in stool is one of the most direct ways to see whether your gut is doing its job. Elevated levels can point toward pancreatic problems, inflammatory bowel disease, or issues with the intestinal lining itself, often before imaging or routine blood work picks anything up.

What This Test Actually Measures

A long chain fatty acid is a fatty acid with at least 12 carbon atoms in its backbone. This includes most of the fats you eat, such as oleic acid from olive oil, linoleic acid from seed oils, and the omega-3 and omega-6 fats found in fish and nuts. Some very long chain fatty acids (more than 22 carbons) are also captured in this test.

The fat in your stool comes from three sources: undigested dietary fat that escaped absorption, fat produced or transformed by the bacteria in your gut, and a small amount from shed intestinal cells. When levels are high, the dominant source is almost always undigested food fat. That means the test reflects the combined performance of pancreatic enzymes, bile, and the intestinal wall itself.

Cystic Fibrosis and Pancreatic Problems

This is the clearest clinical use case for the test. Pancreatic enzymes digest fat into small pieces that the gut can absorb. When the pancreas cannot produce enough of these enzymes, fat spills into stool. But enzyme deficiency is not the only culprit.

In cystic fibrosis, even patients taking pancreatic enzyme replacement often continue to have elevated fecal fat. A study in children with CF found that residual fat malabsorption came from impaired intestinal uptake of long chain fatty acids rather than lack of enzymes, meaning the gut wall itself was struggling to absorb the fatty acids even after digestion had broken them down. This is the kind of finding a standard lab panel cannot pick up.

Inflammatory Bowel Disease

The inflamed intestine handles fat differently than a healthy one. In IBD (inflammatory bowel disease), fecal levels of specific LCFAs shift in ways that track with disease activity.

In one study, nervonic acid, a very long chain fatty acid, was significantly elevated in stool from IBD patients compared to controls, and the levels correlated with standard inflammation markers like calprotectin and C-reactive protein. A separate analysis found that arachidonic acid, adrenic acid, and dihomo-gamma-linolenic acid, all omega-6 family LCFAs, also rose with IBD severity. These findings suggest LCFA profiling may complement calprotectin as a noninvasive way to monitor whether inflammation is flaring.

Obesity and Metabolic Health

A study of 51 people compared the stool of those with severe obesity to lean controls. People with obesity had higher fecal levels of n-3 and n-6 PUFAs (polyunsaturated fatty acids). Whether this reflects altered digestion, shifts in gut bacteria, or something else is still being worked out, but it suggests the gut handles dietary fats differently in the setting of obesity.

Reference Ranges

Long chain fatty acids are reported as one component of a broader fecal fat panel. No universal clinical cutpoint has been standardized for LCFAs as a standalone number, and ranges differ across labs and assay methods. The values below come from research contexts and are intended as orientation only. Your lab will likely report different numbers, possibly in different units, and your report should be interpreted within the reference range your specific lab provides.

Compare your results within the same lab over time for the most meaningful trend. Mixing results from different labs can produce misleading shifts that reflect assay differences rather than real changes in your body.

Tracking Your Trend

A single fecal fat reading is a snapshot. What you ate in the days before the test, your transit time, and even the bacteria in your gut can all push the number around. That is why serial testing is more useful than treating one result as definitive.

Get a baseline when you first want to investigate symptoms or confirm suspected malabsorption. If you start an intervention such as pancreatic enzyme replacement or a specific diet, retest in 6 to 12 weeks to see if the trajectory is moving. After that, annual testing is reasonable if your condition is stable, and more frequent testing is appropriate during symptom flares or treatment changes. The trend matters more than any single value.

What to Do If Your Result Is High

An elevated fecal LCFA level tells you fat is leaking through, but it does not tell you why. The next step is identifying the mechanism. The most useful companion tests are fecal elastase-1, which screens for pancreatic enzyme insufficiency, and fecal calprotectin, which flags intestinal inflammation. Together, these three numbers narrow the cause quickly.

If fecal elastase-1 is low, pancreatic enzyme replacement is the first-line intervention and a gastroenterologist can confirm chronic pancreatitis or another cause. If calprotectin is high, inflammatory bowel disease is on the table and endoscopy is usually the next step. If both of those look normal but fat is still spilling, bile acid problems, small bowel bacterial overgrowth, celiac disease, or short bowel syndrome move up the list, and a breath test and celiac panel are reasonable additions. The pattern of results, not any single number, drives the workup.

When Results Can Be Misleading

A few real-world factors can distort a single reading and send you down the wrong diagnostic path. Keep these in mind when interpreting your result:

• Recent dietary fat intake: a very low-fat diet in the days before testing can produce a falsely reassuring result, while a binge of fatty food can push numbers up transiently without indicating disease. Standardized fat intake before collection matters for chronic pancreatitis workups.
• Orlistat and other lipase inhibitors: orlistat blocks fat absorption by design and will raise fecal fat substantially. Silibinin, a compound in milk thistle extract, has the same effect. If you are taking either, the result does not reflect your underlying digestion.
• Medium-chain triglyceride supplements: MCT oil is absorbed through a different pathway than long chain fats and can shift the fecal fat profile in ways that look like malabsorption has resolved, even if the underlying problem remains.
• Stool consistency and collection errors: very watery or incomplete stool samples can skew quantification. Follow collection instructions carefully and report any diarrhea or recent antibiotic use.